2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1

BACKGROUND: 2,5-dimethylcelecoxib (DMC) is a targeted inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1), a key enzyme in the PGE2 synthesis pathway of inflammatory mediators. Previous studies have confirmed that DMC can inhibit the growth of hepatitis B virus (HBV)-related hepatocellular...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhanfei, Chen, Yiyin, Peng, Lirong, Wang, Xiaoqian, Tang, Nanhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542662/
https://www.ncbi.nlm.nih.gov/pubmed/33028694
http://dx.doi.org/10.1136/jitc-2020-001377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542662/
https://www.ncbi.nlm.nih.gov/pubmed/33028694
http://dx.doi.org/10.1136/jitc-2020-001377

Ejemplares similares